ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), announced on October 17, 2022, a Medical Device Correction for all Omnipod DASH® Personal Diabetes Managers ...

The FDA posted a notice saying the recall of Insulet's Omnipod DASH Insulin Management System Personal Diabetes Manager is a Class I, the most serious recall indicating the devices could cause serious ...

Insulet has begun a voluntary recall of the remote-control devices used with its Omnipod Dash insulin pumps after discovering that the devices’ batteries may be at risk of swelling, leaking or ...

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced ...

Insulet Corporation’s PODD Omnipod and Omnipod DASH insulin management systems recently received FDA’s approval for their use with Eli Lilly and Company’s LLY Lyumjev (insulin lispro-aabc injection) ...

Omnipod 5 has been a major revenue catalyst for Insulet since its release. At the same time, operating expenses associated with Omnipod 5 are higher because of demand exceeding expectations. Higher ...

Billerica, Massachusetts-based Insulet Corporation, maker of the OmniPod Insulin pump, has just announced that it received the FDA clearance to commercialize its latest product the Omnipod Dash ...

Pease announced, "For the fourth quarter, we expect total Omnipod revenue growth of 27% to 30% and total company growth of 25% to 28%." She guided for fourth quarter U.S. Omnipod growth of 24% to 27% ...